RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
  AIDS
  Anthrax
  Dengue
  Ebola
  HCV
  Influenza
  Leishmaniasis
  Malaria
  MRSA
  Mumps
  Pertussis
  Prion Diseases
  SARS
  Shigella
  Small Pox
  Tuberculosis
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Oct 11, 2012 - 10:22:56 PM
SARS Channel

subscribe to SARS newsletter
Latest Research : Infectious Diseases : SARS

   EMAIL   |   PRINT
Immune Response Differs in SARS Patients

Apr 15, 2005 - 5:05:00 PM
The disease itself differs from other non-SARS viral infections that cause no increase in IP-10. The researchers believe that levels of the protein could make a difference in both diagnosis and the development of an effective treatment for the disease.

 
[RxPG] Chinese investigators have revealed that the early presence of interferon-inducible protein 10 (IP-10), an immunoregulatory protein, is a prominent characteristic of the body's immune reaction to the coronavirus that causes severe acute respiratory syndrome (SARS). The disease itself differs from other non-SARS viral infections that cause no increase in IP-10. The researchers believe that levels of the protein could make a difference in both diagnosis and the development of an effective treatment for the disease.

The investigators screened 14 cytokines/chemokines (immunoregulatory proteins) in the blood of 23 patients with SARS and 25 non-SARS patients with atypical pneumonia. The SARS patients were separated into 4 groups, according the disease's course: early stage---2 days after onset of fever; progressive stage--10 to 20 days after onset; end stage--the day before death; and convalescent stage--15 to 30 days after discharge from the hospital.

They said that IP-10 was markedly elevated in the blood during the early stage of SARS, and remained at a high level during convalescence. Also, they said that IP-10 was highly expressed in both lung and lymphoid tissues.

The investigators pointed out that immunopathologic injury of host cells triggered by the immune response to virus plays a key role in the pathogenesis of virus infections. Many cytokines/chemokines released from activated immune cells not only take part in the process of antiviral immune response, but are also involved in cell damage and development of organ dysfunction. Determination of these soluble factors in the blood should aid their understanding of the immunologic processes of SARS and enable differential diagnosis of SARS from other atypical pneumonias that require quite different approaches to the management of patients.



Publication: The study was published in the second issue for April 2005 of the American Thoracic Society's peer-reviewed American Journal of Respiratory and Critical Care Medicine.
On the web: www.thoracic.org 

Advertise in this space for $10 per month. Contact us today.


Related SARS News
A Macaque Model of SARS
Researchers probe papain-like-protease (PLpro) enzyme that may lead to new SARS drugs
Benzotriazole Esters Based Enzyme inhibitors block replication of SARS virus
SARS Can Infect Brain Tissue
Cinanserin May Offer New Hope in Treating SARS
A Prototype drug for SARS
Immune Response Differs in SARS Patients

Subscribe to SARS Newsletter

Enter your email address:


 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)